Global Obesity Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Type;
Bupropion & Naltrexone, Orlistat, Lorcaserin, Phentermine & Topiramate, and Liraglutide.By Surgery Type;
Gastric Bypass Surgery, Adjustable Gastric Banding Surgery, Gastric Sleeve Surgery, Duodenal Switch Surgery, and Others.By Diagnosis;
Appetite Suppressants, Combination Drugs, Malabsorption, and Satiety Drugs.By End User;
Hospitals, and Clinics.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Obesity Treatment Market (USD Million), 2021 - 2031
In the year 2023, the Global Obesity Treatment Market was valued at USD 8,648.25 million. The size of this market is expected to increase to USD 22,082.56 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 14.3%.
Pharmaceutical treatments form a substantial segment of the market, consisting of medications that target appetite suppression, fat absorption inhibition, or metabolic regulation. These drugs are often prescribed in conjunction with lifestyle modifications to enhance effectiveness in weight management and health improvement. Surgical interventions play a crucial role, particularly for individuals with severe obesity or those who have failed to achieve significant weight loss through non-surgical means. Procedures like gastric bypass, sleeve gastrectomy, and gastric banding are designed to alter digestive processes or reduce stomach capacity, facilitating weight loss and metabolic improvements.
Medical devices also contribute to the market by providing minimally invasive options for weight management. Devices such as gastric balloons, which occupy space in the stomach to induce feelings of fullness, and neuromodulation devices, which alter nerve signals to regulate appetite and metabolism, offer alternatives to surgery for certain patient populations. Non-pharmacological approaches remain fundamental in obesity treatment, emphasizing lifestyle modifications such as dietary changes, increased physical activity, behavioral therapy, and counseling. These interventions aim not only to achieve weight loss but also to foster sustainable habits that support long-term health and well-being.
Global Obesity Treatment Market Recent Developments
-
In February 2022, Pfizer conducted research on an oral diabetes drug targeting glucagon-like peptide-1 receptors, suggesting its effectiveness in managing type 2 diabetes and promoting weight loss. This finding was significant, as obesity is often linked to type 2 diabetes complications.
-
In November 2021, Novo Nordisk announced that the European regulator, the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion recommending marketing authorization of Wegovy for chronic weight management in obese adults, marking a significant step in obesity treatment options.
Segment Analysis
The Global Obesity Treatment Market has been segmented by Drug Type, Surgery Type, Diagnosis, End User, and Geography to provide a comprehensive view of the market. In terms of Drug Type, the market includes a variety of medications aimed at weight loss, such as Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, and Liraglutide. These drugs are prescribed to individuals who are obese or overweight, offering treatment options ranging from appetite suppression to fat absorption inhibition, contributing significantly to the overall market growth.
Surgery Type plays a crucial role in obesity treatment, particularly for individuals with severe obesity or those who have not achieved significant weight loss through medications or lifestyle changes. The primary surgical interventions include bariatric surgery options such as gastric bypass, gastric sleeve, and gastric banding. These surgeries are highly effective in achieving significant and lasting weight loss, and their growing adoption due to their success rate is a key driver for the market. As more patients seek surgical solutions, the demand for these procedures is expected to rise, influencing market dynamics.
Diagnosis is an essential part of the obesity treatment process, helping to identify individuals who are candidates for drug therapy or surgery. Tools such as body mass index (BMI) measurement, blood tests, and imaging techniques assist healthcare providers in diagnosing obesity and assessing related comorbidities. The End User segment of the market includes healthcare facilities like hospitals, clinics, and specialized weight management centers. These institutions play a vital role in delivering obesity treatment through both medical and surgical interventions. Geographically, the market is segmented across regions such as North America, Europe, Asia-Pacific, and Latin America, with North America holding the largest share due to the high prevalence of obesity and the availability of advanced treatment options.
Global Obesity Treatment Segment Analysis
In this report, the Global Obesity Treatment Market has been segmented by Drug Type, Surgery Type, Diagnosis, End User and Geography.
Global Obesity Treatment Market, Segmentation by Drug Type
The Global Obesity Treatment Market has been segmented by Drug Type into Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate and Liraglutide.
The Global Obesity Treatment Market has been segmented by Drug Type, with various pharmaceutical options available for managing and treating obesity. Among the prominent drug types, Bupropion and Naltrexone are often prescribed together as a combination therapy aimed at reducing weight by curbing appetite and enhancing energy expenditure. This drug combination is gaining traction due to its ability to address both the emotional and metabolic components of obesity. It is primarily used for individuals who are severely obese or have obesity-related comorbidities.
Orlistat is another widely used medication in obesity treatment, working by inhibiting the enzyme lipase, which is responsible for the breakdown of fats in the digestive system. This leads to reduced fat absorption and weight loss. Orlistat is often recommended for overweight or obese patients with health conditions such as diabetes or hypertension, providing a non-systemic, well-tolerated treatment option. The demand for Orlistat continues to grow due to its availability in both prescription and over-the-counter forms, making it accessible to a broad range of patients.
Other drug types such as Lorcaserin, Phentermine and Topiramate, and Liraglutide have also found strong usage in obesity management. Lorcaserin works by affecting serotonin receptors in the brain, promoting satiety and reducing food intake. Phentermine and Topiramate are combined to reduce appetite and increase energy expenditure. These medications are often prescribed to those who have failed to achieve significant weight loss through lifestyle changes alone. Lastly, Liraglutide, originally used for diabetes management, is gaining popularity for its ability to reduce appetite and promote weight loss. The growing number of drug options helps cater to different obesity-related needs, driving the market's growth.
Global Obesity Treatment Market, Segmentation by Surgery Type
The Global Obesity Treatment Market has been segmented by Surgery Type into Gastric Bypass Surgery, Adjustable Gastric Banding Surgery, Gastric Sleeve Surgery, Duodenal Switch Surgery and Others.
The Global Obesity Treatment Market has seen significant growth, particularly in the surgical segment, as obesity rates continue to rise globally. One of the primary surgery types in this market is gastric bypass surgery. This procedure, often considered the gold standard in bariatric surgery, involves rerouting the small intestine to a smaller stomach pouch, effectively reducing the amount of food that can be consumed and absorbed. Gastric bypass surgery not only helps with weight loss but also improves or resolves obesity-related conditions such as type 2 diabetes, hypertension, and sleep apnea. The continued success and effectiveness of this procedure contribute to its popularity, making it a key driver in the obesity treatment market.
Another common surgical option is adjustable gastric banding surgery. In this procedure, a band is placed around the upper portion of the stomach, creating a small pouch and restricting food intake. The band is adjustable, allowing doctors to control the size of the stomach pouch based on the patient's progress. While this procedure has a lower risk of complications compared to gastric bypass surgery, it is generally less effective for long-term weight loss. Nevertheless, adjustable gastric banding remains a popular choice for patients seeking a less invasive option and is still widely used in the treatment of obesity, particularly in patients with a lower body mass index (BMI).
Gastric sleeve surgery (or sleeve gastrectomy) is another prominent procedure in the obesity treatment market. In this surgery, a large portion of the stomach is removed, leaving a narrow "sleeve" that limits food intake. This procedure has gained popularity due to its effectiveness in weight loss and its relatively low complication rates. Gastric sleeve surgery has also been shown to provide long-term benefits, with patients often achieving significant weight loss and experiencing improvements in obesity-related conditions. Duodenal switch surgery, a more complex and less common procedure, involves both a sleeve gastrectomy and a rerouting of the small intestine to reduce calorie absorption. It offers substantial weight loss results but carries a higher risk of complications. The others category includes less common or emerging surgeries, such as biliopancreatic diversion, that are still being explored or used in specific cases. Each of these surgical options offers different benefits and risks, catering to diverse patient needs and preferences in the obesity treatment market.
Global Obesity Treatment Market, Segmentation by Diagnosis
The Global Obesity Treatment Market has been segmented by Diagnosis into Appetite Suppressants, Combination Drugs, Malabsorption, and Satiety Drugs.
Appetite suppressants are medications that act on the central nervous system to reduce feelings of hunger, helping individuals consume fewer calories and achieve weight loss. These drugs typically target neurotransmitters involved in appetite regulation, such as serotonin and norepinephrine, to promote satiety and control food intake. Combination drugs combine multiple therapeutic agents with complementary mechanisms of action to enhance weight loss efficacy. These combinations may include appetite suppressants alongside drugs that address metabolic processes or hormonal imbalances contributing to obesity, offering a comprehensive approach to weight management.
Malabsorption therapies work by reducing the absorption of dietary fats or nutrients in the gastrointestinal tract, thereby limiting calorie intake and promoting weight loss. Drugs in this category inhibit enzymes responsible for fat digestion or alter bile acid metabolism, resulting in reduced energy absorption from food consumed.
Satiety drugs target hormones or receptors involved in signaling feelings of fullness and satisfaction after eating. By modulating these pathways, satiety drugs help individuals control portion sizes, reduce cravings, and maintain healthier eating habits, supporting sustainable weight loss efforts.
Global Obesity Treatment Market, Segmentation by End User
The Global Obesity Treatment Market has been segmented by End User into Hospitals, and Clinics.
The Global Obesity Treatment Market has been segmented by End User into Hospitals and Clinics, with each segment playing a pivotal role in the delivery of obesity treatments. Hospitals are major healthcare providers for individuals with severe obesity, particularly those seeking surgical interventions such as bariatric surgery. Hospitals offer specialized departments equipped with advanced medical technologies and experienced surgeons capable of performing complex surgeries like gastric bypass, sleeve gastrectomy, and other weight loss procedures. Additionally, hospitals provide comprehensive care, including pre-surgery evaluations, post-surgery monitoring, and the management of obesity-related comorbidities such as diabetes and hypertension, which significantly contribute to their dominant role in the market.
Clinics, on the other hand, cater primarily to individuals seeking non-surgical treatments, such as weight loss medications, dietary counseling, and lifestyle modifications. These facilities may specialize in obesity management, offering personalized treatment plans tailored to the individual’s needs. Clinics are an essential part of the market for individuals with less severe obesity or those who are not ready for surgery. Many clinics also offer medical weight loss programs, which may include medications like orlistat or phentermine, as well as behavioral therapy and nutritional counseling to help individuals achieve long-term weight management. The accessibility and affordability of clinics make them a significant segment in the market.
Both Hospitals and Clinics are crucial in addressing the growing obesity epidemic, with hospitals typically handling more complex and high-risk cases, while clinics provide ongoing care and management for patients. The growth of the Obesity Treatment Market is influenced by the increasing demand for obesity treatments in both settings, driven by rising obesity rates globally. As the awareness of obesity-related health risks continues to rise, both hospitals and clinics are expected to see continued growth in their patient populations, driving further advancements in treatment options and services.
Global Obesity Treatment Market, Segmentation by Geography
In this report, the Global Obesity Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Obesity Treatment Market Share (%), by Geographical Region, 2024
North America, comprising the United States and Canada primarily, holds a prominent position in the global market due to high obesity prevalence rates and robust healthcare systems. The region leads in research and development of obesity treatments, including pharmaceuticals, surgical interventions such as bariatric surgery, and comprehensive lifestyle modification programs aimed at managing and preventing obesity-related complications.
Europe follows closely, encompassing countries with diverse healthcare frameworks and varying obesity rates across the continent. Western European nations typically lead in market size and innovation, driven by stringent health regulations and government initiatives promoting public health and wellness. Eastern Europe, while showing lower obesity rates historically, is witnessing increasing trends, driving demand for effective obesity treatments and preventive measures.
Asia Pacific emerges as a region of significant growth potential, fueled by rapid urbanization, changing dietary habits, and rising obesity rates in countries like China, India, and Japan. Governments and healthcare providers are increasingly focusing on obesity prevention and treatment strategies, leveraging technological advancements and adapting global best practices to local contexts. Middle East and Africa face unique challenges with obesity prevalence influenced by socio-economic factors, cultural norms, and access to healthcare services. Efforts in these regions are focused on raising awareness, improving healthcare infrastructure, and implementing effective obesity management programs to address growing health concerns.
Latin America, characterized by diverse healthcare systems and varying economic conditions, is witnessing an upward trend in obesity prevalence, particularly in urban areas. Governments and healthcare stakeholders are collaborating to implement policies that promote healthy lifestyles and enhance access to obesity treatment options, including both medical and surgical interventions.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Obesity Treatment Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers, Restraints and Opportunity Analysis
Drivers
- Rising obesity rates
- Technological advancements
-
Increasing healthcare spending - Healthcare spending dedicated to obesity treatment encompasses expenditures on pharmaceuticals, surgical interventions, medical devices, and healthcare services tailored to managing obesity and its associated comorbidities. Governments, private insurers, and healthcare providers are allocating greater resources to combat obesity due to its profound impact on population health and healthcare system sustainability.
The rise in healthcare spending is driven by several factors. Firstly, the escalating prevalence of obesity globally has led to higher demand for obesity treatment services and interventions. Healthcare systems are responding by expanding obesity clinics, enhancing diagnostic capabilities, and investing in specialized treatment facilities within hospitals and clinics. Secondly, advancements in medical research and technology have spurred the development of innovative therapies and interventions for obesity. This includes the introduction of novel pharmaceuticals that target appetite regulation or metabolic pathways, as well as advancements in surgical techniques for weight loss such as minimally invasive bariatric procedures.
Increasing awareness and advocacy efforts surrounding obesity-related health risks have amplified public and governmental support for proactive healthcare spending. Initiatives promoting healthy lifestyles, nutrition education, and community-based obesity prevention programs receive funding to mitigate the societal and economic burden of obesity-related healthcare costs. Healthcare spending on obesity treatment is influenced by regulatory frameworks and policies aimed at improving access to healthcare services and promoting equitable health outcomes for all population groups, including underserved communities disproportionately affected by obesity.
Restraints
- High treatment costs
- Safety concerns
-
Limited insurance coverage - One of the primary challenges is the classification of obesity treatments as elective or cosmetic procedures by some insurance providers, leading to limited coverage or outright denial of claims. This classification contrasts with the medical consensus that obesity is a complex medical condition requiring comprehensive treatment and management strategies. Coverage limitations may extend to specific treatments such as pharmacotherapy, surgical interventions like bariatric surgery, and medical devices designed for weight management. Insurance companies often impose strict eligibility criteria, including BMI thresholds or documented failed attempts at non-surgical weight loss methods, which can restrict access to necessary treatments for individuals struggling with severe obesity.
Disparities in insurance coverage contribute to inequities in access to obesity treatment services, particularly affecting underserved populations and economically disadvantaged individuals who may already face barriers to healthcare access. This limitation not only impacts patient outcomes but also increases healthcare costs associated with obesity-related comorbidities that could potentially be prevented or managed more effectively with timely and comprehensive treatment.
Addressing the issue of limited insurance coverage requires collaborative efforts from healthcare providers, policymakers, insurance companies, and advocacy groups. Advocating for broader insurance coverage policies that recognize obesity as a chronic disease requiring medically necessary treatment is crucial. Enhancing public and professional awareness about the benefits of comprehensive obesity management and the cost-effectiveness of early intervention can support efforts to expand insurance coverage and improve access to evidence-based treatments.
Opportunities
- Emerging markets
- Personalized medicine
-
Non-surgical interventions - Non-surgical interventions in obesity treatment encompass a wide range of approaches aimed at promoting weight loss, improving metabolic health, and reducing obesity-related complications without the need for surgical procedures. These interventions are particularly attractive to individuals seeking alternatives to surgery or those who do not qualify for surgical options due to health considerations.
One prominent non-surgical intervention includes lifestyle modification programs, which focus on dietary changes, increased physical activity, and behavioral therapy. These programs are designed to promote sustainable weight loss by encouraging healthier eating habits, regular exercise, and addressing psychological factors contributing to overeating. Medical therapies form another crucial aspect of non-surgical interventions, involving the use of pharmacological agents that target appetite regulation, fat metabolism, or satiety mechanisms. Medications such as appetite suppressants, combination drugs, and metabolic regulators are prescribed to assist patients in achieving and maintaining weight loss goals under medical supervision.
Behavioral interventions play a vital role in supporting long-term weight management by addressing psychological and behavioral factors influencing eating behaviors and adherence to treatment plans. Behavioral therapy techniques, counseling sessions, and support groups help patients develop coping strategies, manage stress, and sustain lifestyle changes essential for successful weight loss outcomes.
Competitive Landscape Analysis
Key players in Global Obesity Treatment Market include:
- Mediflex Surgical Products
- Covidien plc
- Olympus Corporation
- Takeda Pharmaceuticals Company Limited
- Eisai Co Ltd
- Novo Nordisk A/S
- Zafgen
- Rhythm Pharmaceuticals
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Surgery Type
- Market Snapshot, By Diagnosis
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Obesity Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Rising obesity rates
-
Technological advancements
-
Increasing healthcare spending
-
- Restraints
-
High treatment costs
-
Safety concerns
-
Limited insurance coverage
-
- Opportunities
-
Emerging markets
-
Personalized medicine
-
Non-surgical interventions
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Obesity Treatment Market, By Drug Type, 2021 - 2031 (USD Million)
- Bupropion and Naltrexone
- Orlistat
- Lorcaserin
- Phentermine and Topiramate
- Liraglutide
- Global Obesity Treatment Market, By Surgery Type, 2021 - 2031 (USD Million)
- Gastric Bypass Surgery
- Adjustable Gastric Banding Surgery
- Gastric Sleeve Surgery
- Duodenal Switch Surgery
- Others
- Global Obesity Treatment Market, By Diagnosis, 2021 - 2031 (USD Million)
-
Appetite Suppressants
-
Combination Drugs
-
Malabsorption
-
Satiety Drugs
-
- Global Obesity Treatment Market, By End User, 2021 - 2031 (USD Million)
-
Hospitals
-
Clinics
-
- Global Obesity Treatment Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Obesity Treatment Market, By Drug Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Mediflex Surgical Products
- Covidien plc
- Olympus Corporation
- Takeda Pharmaceuticals Company Limited
- Eisai Co Ltd
- Novo Nordisk A/S
- Zafgen
- Rhythm Pharmaceuticals
- Company Profiles
- Analyst Views
- Future Outlook of the Market